Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Okin, R. Devereux, S. Jern, S. Kjeldsen, S. Julius, M. Nieminen, S. Snapinn, K. Harris, P. Aurup, J. Edelman, B. Dahlöf (2003)
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) StudyCirculation: Journal of the American Heart Association, 108
S.E. Kjeldsen, B. Dahlof, R.B. Devereux (2000)
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE studyAm J Hypertens, 13
J. Mathew, P. Sleight, E. Lonn (2001)
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Heart Outcomes Prevention Evaluation (HOPE) InvestigatorsCirculation, 104
J. Mathew, P. Sleight, E. Lonn, David Johnstone, J. Pogue, Q. Yi, J. Bosch, B. Sussex, J. Probstfield, S. Yusuf (2001)
Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor RamiprilCirculation: Journal of the American Heart Association, 104
M. Azizi, Gilles Chatellier, T. Guyene, Dalia Murieta-Geoffroy, J. Ménard (1995)
Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.Circulation, 92 4
R.B. Devereux, M.J. Roman, V. Palmieri (2000)
Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertensionJ Hypertens, 18
M.-W. Lo, M. Golberg, J. McCrea (1995)
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humansClin Pharmacol Ther, 58
K. Goa, A. Wagstaff (1996)
Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertensionDrugs, 51
S.E. Kjeldsen, B. Dalhöf, R.B. Devereux (2002)
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudyJAMA, 288
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs; results of prospectively designed overviews of randomised trials. Blood Pressure Treatment Trialists’ CollaborationLancet, 356
P. Timmermans, P. Wong, A.T. Chiu (1993)
Angiotensin II receptors and angiotensin II receptor antagonistsPharmacol Rev, 45
K.L. Simpson, K.J. McClellan (2000)
Losartan: a review of its use, with special focus on elderly patientsDrugs Aging, 16
B. Dalhöf, R.B. Devereux, S.E. Kjeldsen (2002)
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet, 359
B. Dalhöf, R. Devereux, S. Julius (1998)
Characteristics of 9194 patients with left ventricular hypertrophy in the LIFE studyHypertension, 32
P. Verdecchia, G. Schillaci, C. Borgioni, A. Ciucci, R. Gattobigio, I. Zampi, G. Reboldi, C. Porcellati (1998)
Prognostic significance of serial changes in left ventricular mass in essential hypertension.Circulation, 97 1
R. Cody (1994)
The clinical potential of renin inhibitors and angiotensin antagonistsDrugs, 47
(1999)
World Health Organisation -International Society of Hypertension Guidelines for the Management of HypertensionJ Hypertens, 17
R. Davis, P. Benfield (1997)
Management of primary hypertension: the potential role of losartanDis Manage Health Outcomes, 1
M. Burnier, B. Rutschmann, J. Nussberger (1993)
Salt-dependent renal effects of an angiotensin II antagonist in healthy subjectsHypertension, 22
Rick Davis, P. Benfield (1997)
Management of Primary HypertensionDisease Management & Health Outcomes, 1
B. Neal, S. MacMahon, N. Chapman (2000)
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trialsThe Lancet, 356
C. Erly, B. Bader, M. Scheu (1995)
Renal hemodynamics in essential hypertensives treated with losartanClin Nephral, 43
M. Muiesan, M. Salvetti, D. Rizzoni, M. Castellano, F. Donato, E. Agabiti-Rosei (1995)
Association of change in left ventricular mass with prognosis during long-term antihypertensive treatmentJournal of Hypertension, 13
L.H. Lindholm, H. Ibsen, K. Borch-Johnsen (2002)
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyJ Hypertens, 20
A. Chiu, D. McCall, P. Aldrich (1990)
[3H]DUP753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtypeBiochem Biophys Res Commun, 172
M. Koren, R. Devereux, P. Casale, D. Savage, J. Laragh (1991)
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension.Annals of internal medicine, 114 5
L. Burrell, C. Johnston (1997)
Angiotensin II receptor antagonists: potential in elderly patients with cardiovascular diseaseDrugs Aging, 10
M. Goldberg, W. Tanaka, A. Barchowsky (1993)
Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteersHypertension, 21
L. Lindholm, H. Ibsen, B. Dahlöf, R. Devereux, G. Beevers, U. Faire, F. Fyhrquist, S. Julius, S. Kjeldsen, Krister Kristiansson, O. Lederballe‐Pedersen, M. Nieminen, P. Omvik, S. Oparil, H. Wedel, P. Aurup, J. Edelman, S. Snapinn (2002)
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololThe Lancet, 359
K. Tsunoda, K. Abe, T. Hagino (1993)
Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertensionAm J Hypertens, 6
Y. Christen, B. Waeber, J. Nussberger (1991)
Dose-response relationships following oral administration of DuP753 to normal humansAm J Hypertens, 4
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group
▴ Losartan binds selectively to the angiotensin II subtype 1 receptor, blocking the activity of angiotensin II.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Sep 11, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.